|
Sub-section menu :
|
Content :
Our stakeholders
A company’s ability to respond to stakeholders’ expectations is a measure of its credibility and sustainability. As a diversified global healthcare leader operating in more than 100 countries, Sanofi is well aware of the importance of providing concrete responses to the needs and expectations of a wide variety of stakeholders, particularly those in the healthcare field. In our day-to-day interactions with stakeholders, we seek to deliver appropriate responses whenever we are called upon – for example, to provide reliable and factual information, to participate in constructive dialogue, to form partnerships, to support patient associations, to provide humanitarian assistance, to find innovative solutions for patients and to answer many other needs.
Ongoing stakeholder dialogue
In the past, we have consulted our in-house and external stakeholders on many occasions with a precise purpose in mind – such as for the materiality test. However, starting in 2011, Sanofi’s CSR Direction decided to pursue a more pro-active strategy and establish a dedicated structure to ensure continuous, formal interaction with our external stakeholders. A stakeholder panel was created in late 2011 in France. The first stakeholder meeting will be organized in Q1 of 2012. This new development, one of Sanofi’s 2011 CSR milestones, is supported by leading CSR rules and guidelines (e.g., Global Reporting Initiatives, ISO 26000). Ensuring stakeholder engagement and dialogue on a regular basis will allow us to constantly gain new insights about the CSR landscape and benefit from outside expertise on the CSR challenges facing the Group. Regular contacts with large or small investors are ensured by the Board or company employees acting on its behalf on questions of corporate governance through various channels and events such as Salon Actionaria organized in France, the establishment of a minority shareholder committee, the maintenance of an award winning Investor Relations and Individual Shareholder department, interactions with Proxy Agencies and Social Rating Agencies, and individual outreaches. * For more information: We are exploring approaches to expanding our ongoing dialogue with stakeholders and expect to see exciting developments in this area in 2012.
Different stakeholder relationships correspond to different needs
Our interactions with stakeholders necessarily require differing degrees of involvement – from promoting awareness and communications, to dialogue and consultation, partnerships and collaboration. The following table outlines our primary stakeholder relationships. These stakeholder relationships are managed on a daily basis worldwide and the stakeholder process is a complementary process. The different sections of our CSR Report provide an in-depth account of how these interactions with our many stakeholders have produced results through specific initiatives and actions. Stakeholders| Stakeholders | Communication | Dialogue / Consultation | Collaborations |
|---|
| Employees | - In-house communication tools (intranet, Internet, CSR blog, CSR events)
- Awareness-raising initiatives (training, CSR report, brochures)
| - Dialogue with employees, employee representatives and trade unions
- Direct expression forum
- Raising awareness about sustainable development
- Satisfaction surveys
| - Support for employees' individual projects (spin-offs, NGOs, etc.)
- Calls for CSR projects
|
|---|
| Patients | - Dedicated internet sites
- CSR brochures and reports
- Communication about product safety information
- Communication about proper use of products
- Communication about clinical trials
| - Dialogue / consultation panels with patients and patient organizations
| - Information (prevention, screening, education, treatments) and support for patients and their families
- Support for recycling programs for unused medicines where available
|
|---|
| Citizens | - CSR Internet site
- CSR brochures and reports
- Communication about product safety information
- Communication about clinical trials
| - Forums for dialogue and consultation
| - Information on healthcare prevention, screening and education
- Support for recycling unused medicines
|
|---|
| Healthcare professionals | - Dedicated Internet sites
- Scientific publications
- Communication about product safety and efficacy information
- Communication about clinical trials
| - Working groups
- Scientific meetings
- Development expertise
- Satisfaction surveys
| |
|---|
| Regulatory authorities and agencies | - Pharmacovigilance
- Communication about the Group’s corporate strategy and policy
| - Compliance with standard practice (e.g., registration dossier assessment and inspections)
- Development expertise
- Prescription guidelines, negotiating prices and reimbursements
| - Research partnerships
- Providing medicines and vaccines at no cost / low cost for populations in developing countries
- Prevention and management of health crises
|
|---|
| Other pharmaceutical groups | | - Representation on pharmaceutical industry organizations
| - Research partnerships
- Joint ventures
|
|---|
| Suppliers | - Suppliers Code of Conduct
| - Raising awareness about human rights, working conditions and respect for the environment
- Evaluation
| |
|---|
| NGOs | - Brochures, reports, Internet site
- Customized information sessions
| - Multi-stakeholder associations
- Answering questionnaires
- Participating in forums
- Satisfaction surveys
| - Providing medicines and vaccines at no cost / low cost or selling at differential prices
- Awareness-raising, prevention and training initiatives for NGOs
|
|---|
| Rating agencies | - Brochures, reports, Internet site
| - Answering questionnaires / occasional requests
| |
|---|
| Investors | - Quarterly financial results
- Annual and half-year reports
- Internet site
- Group CSR performance
| - Financial events / meetings of analysts
- Special meetings
- Answering questionnaires / occasional requests
- Roadshows
- Salon Actionaria organized in France
- interactions with Proxy Agencies and Social Rating Agencies
| - Conferences for the financial community
- establishment of a minority shareholder committee
|
|---|
| Individual shareholders | - Letter to shareholders
- Individual shareholder handbook
- Annual review
- Internet site
- Group CSR performance
| - Individual shareholders’ advisory committees
- Specific meetings in France
- General Meeting
- Individual shareholder fairs in France and the United States
| |
|---|
| Local communities | - Brochures and reports
- Open houses
- Special events
| - Panels of local residents
- Dialogue with local authorities
| - Local development initiatives (humanitarian sponsorship, governments, NGOs, etc.)
|
|---|
*The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, is available in the section:
|